Mankind Pharma sets a new benchmark, launching 120 Premium DMF quality drugs for Indian patients

29 August 2023

Shares of Indian generic drugmaker Mankind Pharma (BSE: 543904) edged up 1% today, after it boasted a significant stride with the introduction of 120 DMF (Drug Master File) Quality Medicines in the Indian market.

Committed to delivering exceptional healthcare solutions at affordable rates, Mankind Pharma's initiative aims to ensure universal access to medicines of international calibre, the company noted.

India stands as a global leader in offering generic medicines that adhere to the stringent DMF quality standards set for Active Pharmaceutical Ingredients (APIs). Mankind Pharma takes a pioneering step by introducing DMF quality API in the Indian market, which is manufactured in a US Food and Drug Administration (FDA)-approved plant. Thus, the final medicine is always one of the best quality with better efficacy, the company claims.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK